Overview

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

Status:
Terminated
Trial end date:
2016-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Osmotica Pharmaceutical US LLC
Treatments:
Amantadine
Levodopa